Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label PT-112 in advanced solid tumors with expansion cohort in metastatic castration-resistant prostate cancer
2024-518506-41-00Phase 2Completed
- Sponsor
- Promontory Therapeutics
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of Imifoplatin in prostate cancer (PCa) (2 arms), sponsored by Promontory Therapeutics. Primary endpoint: Recommended dose and schedule for pivotal studies in expansion cohort D. Started Oct 2020; status: completed.
02
Drugs
Imifoplatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-518506-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518506-41-00.